GPCR Modulation in Breast Cancer
AbstractBreast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration. G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors involved in the development and progression of many tumors including breast cancer. Here we discuss data regarding GPCR-mediated signaling, pharmacological properties and biological outputs toward breast cancer tumorigenesis and metastasis. Furthermore, we address several drugs that have shown an unexpected opportunity to interfere with GPCR-based breast tumorigenic signals. View Full-Text
Share & Cite This Article
Lappano, R.; Jacquot, Y.; Maggiolini, M. GPCR Modulation in Breast Cancer. Int. J. Mol. Sci. 2018, 19, 3840.
Lappano R, Jacquot Y, Maggiolini M. GPCR Modulation in Breast Cancer. International Journal of Molecular Sciences. 2018; 19(12):3840.Chicago/Turabian Style
Lappano, Rosamaria; Jacquot, Yves; Maggiolini, Marcello. 2018. "GPCR Modulation in Breast Cancer." Int. J. Mol. Sci. 19, no. 12: 3840.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.